A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
Most Recent Events
- 22 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jun 2009 New trial record